Evidence map›Paper›PMID 33516874›Full record

ArticleNeurobiology of disease2021

Mutant three-repeat tau expression initiates retinal ganglion cell death through Caspase-2.

Jennifer Ngolab, Saranya Canchi, Suhail Rasool, Abderrahman Elmaarouf, Kimberly Thomas, Floyd Sarsoza, Jennifer Grundman, Michael Mante, Jazmin Florio, Nimisha Nandankar and 4 more

Open access · goldAbstract read
In one paragraph

Article in Neurobiology of disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Jennifer NgolabDepartment of Neurosciences, University of California, San Diego, School of Medicine, La Jolla, CA 92093, United States of America.
Saranya CanchiDepartment of Neurosciences, University of California, San Diego, School of Medicine, La Jolla, CA 92093, United States of America; Veterans Affairs San Diego Healthcare System, San Diego, CA 92161, United States of America.
Suhail RasoolDepartment of Neurosciences, University of California, San Diego, School of Medicine, La Jolla, CA 92093, United States of America; Amydis Inc, San Diego, CA 92121, United States of America.
Abderrahman ElmaaroufProthena Biosciences, South San Francisco, CA 94080, United States of America.
Kimberly ThomasProthena Biosciences, South San Francisco, CA 94080, United States of America.
Floyd SarsozaDepartment of Neurosciences, University of California, San Diego, School of Medicine, La Jolla, CA 92093, United States of America; Veterans Affairs San Diego Healthcare System, San Diego, CA 92161, United States of America.
Jennifer GrundmanDepartment of Neurosciences, University of California, San Diego, School of Medicine, La Jolla, CA 92093, United States of America.
Michael ManteDepartment of Neurosciences, University of California, San Diego, School of Medicine, La Jolla, CA 92093, United States of America.
Jazmin FlorioDepartment of Neurosciences, University of California, San Diego, School of Medicine, La Jolla, CA 92093, United States of America.
Nimisha NandankarDepartment of Neurosciences, University of California, San Diego, School of Medicine, La Jolla, CA 92093, United States of America.
Shaina KorouriDepartment of Neurosciences, University of California, San Diego, School of Medicine, La Jolla, CA 92093, United States of America.
Wagner ZagoProthena Biosciences, South San Francisco, CA 94080, United States of America.
Eliezer MasliahDivision of Neuroscience and Laboratory of Neurogenetics, National Institutes on Aging, NIH, Bethesda, MD 20892, United States of America.
Robert A RissmanDepartment of Neurosciences, University of California, San Diego, School of Medicine, La Jolla, CA 92093, United States of America; Veterans Affairs San Diego Healthcare System, San Diego, CA 92161, United States of America. Electronic address: rrissman@health.ucsd.edu.
University of California, San Diego · USProthena (United States) · USNational Institute on Aging · USVA San Diego Healthcare System · US

Funding

UCSD Shiley-Marcos Alzheimer's Disease Research Center P30P30AG062429 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Mark W Bondi · 2019 to 2026
$34.9M
B-Synuclein as a Treatment for Lewy Body DiseaseR01AG018440 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RISSMAN, ROBERT · 2001 to 2021
$5.2M
Neuroimmune responses and therapeutics of alpha-synucleinopathies of the aging populationZIAAG000936 · NIA · NATIONAL INSTITUTE ON AGING · PI COOKSON, MARK · 2017 to 2025
$4.1M
a-synuclein clearance strategies for the treatment of Lewy body disease.R37AG018440 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MASLIAH, ELIEZER · 2006 to 2014
$2.7M
Identifying Molecular Signatures associated with Alzheimer's Disease in the RetinaR21AG070595 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI NGOLAB, JENNIFER, RISSMAN, ROBERT · 2020 to 2020
$434k
NIA NIH HHS P30 AG062429NIA NIH HHS R01 AG018440NIA NIH HHS R21 AG070595NIA NIH HHS R37 AG018440
6 · The paper itself

Abstract

The microtubule-associated protein tau is implicated in multiple degenerative diseases including retinal diseases such as glaucoma; however, the way tau initiates retinopathy is unclear. Previous retinal assessments in mouse models of tauopathy suggest that mutations in four-repeat (4R) tau are associated with disease-induced retinal dysfunction, while shifting tau isoform ratio to favor three-repeat (3R) tau production enhanced photoreceptor function. To further understand how alterations in tau expression impact the retina, we analyzed the retinas of transgenic mice overexpressing mutant 3R tau (m3R tau-Tg), a model known to exhibit Pick's Disease pathology in the brain. Analysis of retinal cross-sections from young (3 month) and adult (9 month) mice detected asymmetric 3R tau immunoreactivity in m3R tau-Tg retina, concentrated in the retinal ganglion and amacrine cells of the dorsal retinal periphery. Accumulation of hyperphosphorylated tau was detected specifically in the detergent insoluble fraction of the adult m3R tau-Tg retina. RNA-seq analysis highlighted biological pathways associated with tauopathy that were uniquely altered in m3R tau-Tg retina. The upregulation of transcript encoding apoptotic protease caspase-2 coincided with increased immunostaining in predominantly 3R tau positive retinal regions. In adult m3R tau-Tg, the dorsal peripheral retina of the adult m3R tau-Tg exhibited decreased cell density in the ganglion cell layer (GCL) and reduced thickness of the inner plexiform layer (IPL) compared to the ventral peripheral retina. Together, these data indicate that mutant 3R tau may mediate toxicity in retinal ganglion cells (RGC) by promoting caspase-2 expression which results in RGC degeneration. The m3R tau-Tg line has the potential to be used to assess tau-mediated RGC degeneration and test novel therapeutics for degenerative diseases such as glaucoma.

Indexed as

AnimalsCaspase 2Cell DeathFemaleHumansMaleMiceMice, TransgenicMutationProtein IsoformsRetinal DiseasesRetinal Ganglion CellsTauopathiestau ProteinsCaspase 2MAPT protein, humanProtein Isoformstau Proteins3 repeat tauAlzheimer's, tauopathyRetinaRetinopathyTau

Identifiers

PMID33516874
PMCPMC8373010
OpenAlexW3127199504

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.